452 related articles for article (PubMed ID: 17545772)
1. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications.
Mankertz J; Schulzke JD
Curr Opin Gastroenterol; 2007 Jul; 23(4):379-83. PubMed ID: 17545772
[TBL] [Abstract][Full Text] [Related]
2. Epithelial tight junctions in intestinal inflammation.
Schulzke JD; Ploeger S; Amasheh M; Fromm A; Zeissig S; Troeger H; Richter J; Bojarski C; Schumann M; Fromm M
Ann N Y Acad Sci; 2009 May; 1165():294-300. PubMed ID: 19538319
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
Hering NA; Schulzke JD
Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.
Heller F; Florian P; Bojarski C; Richter J; Christ M; Hillenbrand B; Mankertz J; Gitter AH; Bürgel N; Fromm M; Zeitz M; Fuss I; Strober W; Schulzke JD
Gastroenterology; 2005 Aug; 129(2):550-64. PubMed ID: 16083712
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction.
Li Q; Zhang Q; Wang M; Zhao S; Ma J; Luo N; Li N; Li Y; Xu G; Li J
Clin Immunol; 2008 Jan; 126(1):67-80. PubMed ID: 17964857
[TBL] [Abstract][Full Text] [Related]
6. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
7. Disrupted barrier function through epithelial cell apoptosis.
Schulzke JD; Bojarski C; Zeissig S; Heller F; Gitter AH; Fromm M
Ann N Y Acad Sci; 2006 Aug; 1072():288-99. PubMed ID: 17057208
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
[TBL] [Abstract][Full Text] [Related]
9. Dislocation of tight junction proteins without F-actin disruption in inactive Crohn's disease.
Oshitani N; Watanabe K; Nakamura S; Fujiwara Y; Higuchi K; Arakawa T
Int J Mol Med; 2005 Mar; 15(3):407-10. PubMed ID: 15702229
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.
Fischer A; Gluth M; Pape UF; Wiedenmann B; Theuring F; Baumgart DC
Am J Physiol Gastrointest Liver Physiol; 2013 Jun; 304(11):G970-9. PubMed ID: 23538493
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of diarrhea in inflammatory bowel diseases.
Binder HJ
Ann N Y Acad Sci; 2009 May; 1165():285-93. PubMed ID: 19538318
[TBL] [Abstract][Full Text] [Related]
12. Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: a novel model for studying the pathomechanisms of inflammatory bowel disease cytokines.
Amasheh M; Grotjohann I; Amasheh S; Fromm A; Söderholm JD; Zeitz M; Fromm M; Schulzke JD
Scand J Gastroenterol; 2009; 44(10):1226-35. PubMed ID: 19658020
[TBL] [Abstract][Full Text] [Related]
13. Tight junctions and cell-cell interactions.
Utech M; Brüwer M; Nusrat A
Methods Mol Biol; 2006; 341():185-95. PubMed ID: 16799199
[TBL] [Abstract][Full Text] [Related]
14. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.
Dignass AU; Baumgart DC; Sturm A
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888
[TBL] [Abstract][Full Text] [Related]
15. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells.
Li N; Gu L; Qu L; Gong J; Li Q; Zhu W; Li J
Eur J Pharm Sci; 2010 Apr; 40(1):1-8. PubMed ID: 20149867
[TBL] [Abstract][Full Text] [Related]
16. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease.
Zeissig S; Bürgel N; Günzel D; Richter J; Mankertz J; Wahnschaffe U; Kroesen AJ; Zeitz M; Fromm M; Schulzke JD
Gut; 2007 Jan; 56(1):61-72. PubMed ID: 16822808
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition.
Willemsen LE; Hoetjes JP; van Deventer SJ; van Tol EA
Clin Exp Immunol; 2005 Nov; 142(2):275-84. PubMed ID: 16232214
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1.
Fischer A; Gluth M; Weege F; Pape UF; Wiedenmann B; Baumgart DC; Theuring F
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(3):G218-28. PubMed ID: 24309183
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease and the apical junctional complex.
Bruewer M; Samarin S; Nusrat A
Ann N Y Acad Sci; 2006 Aug; 1072():242-52. PubMed ID: 17057204
[TBL] [Abstract][Full Text] [Related]
20. Altered claudin expression is a feature of chronic plaque psoriasis.
Watson RE; Poddar R; Walker JM; McGuill I; Hoare LM; Griffiths CE; O'neill CA
J Pathol; 2007 Aug; 212(4):450-8. PubMed ID: 17582238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
